Business
MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN
MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN C...
About this update from Medicure Inc.
[{"type":"text","content":"\n \n \n \n MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n WINNIPEG, MB\n \n \n ,\n \n \n March 23, 2022\n \n \n /CNW/ - Medicure Inc. (\"\n \n Medicure\n \n \" or the \"\n \n Company\n \n \") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in\n \n the United States\n \n market, today reported that Chief Financial Officer\n \n David Gurvey\n \n (CPA, CMA, B.Sc.) is resigning, effective\n \n March 25, 2022\n \n .\n \n \n \n Albert D. Friesen\n \n , PhD, CEO and Chair of the Board of Directors, stated, \"On behalf of everyone at Medicure and our Board of Directors, we thank David for his contributions to our Company and we wish him well in his future endeavors.\"\n \n \n The Company has initiated a search for a new Chief Financial Officer with the capabilities and qualifications to accelerate Medicure's growth and business strategy. Dr.\n \n Neil Owens\n \n , Chief Operating Officer of the Company, will assume the role of interim Chief Financial Officer upon Mr. Gurvey's resignation.\n \n \n \n About Medicure Inc.\n \n \n Medicure is a pharmaceutical company focused on the development and commercialization of innovative and affordable therapeutics for the U.S. market. Medicure's sales force markets to physicians and other healthcare professionals and now with E-Commerce integration, will be offering patients and providers direct online ordering and home delivery. Our vision is to become a leading pharmaceutical company within the U.S, offering a growing portfolio of products that improve patients' lives. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in\n \n the United States\n \n , where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug®, Inc. (\"Marley Drug\"),...